Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Proteostasis Therapeutics, Inc. (NASDAQ: PTI).

Full DD Report for PTI

You must become a subscriber to view this report.


Recent News from (NASDAQ: PTI)

Proteostasis Announces Formation of Independent Steering Committee of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for PTI-428 in Cystic Fibrosis
BRIGHTON, Mass. , May 8, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional prote...
Source: PR Newswire
Date: May, 08 2018 07:00
Lifshitz & Miller LLP Announces Investigation of Acadia Pharmaceuticals Inc., Allegiant Travel Company, Camping World Holdings, Inc., Finish Line, Inc., Myriad Genetics, Inc., Proteostasis Therapeutics, Inc., Under Armour, Inc. and United Community Bancor
NEW YORK , April 24, 2018 /PRNewswire/ --   Acadia Pharmaceuticals Inc. (ACAD) Lifshitz & Miller  announces investigation into possible securities law violations in connection with a report that Acadia's drug Nuplazid has been associated with more than 700 deaths. ...
Source: PR Newswire
Date: April, 24 2018 12:32
TDN on board with Proteostasis' mid-stage study of cystic fibrosis candidate PTI-428
Proteostasis Therapeutics (NYSE: PTI ) is up  6%  premarket on light volume on the heels of its announcement that the Therapeutics Development Network (TDN), the drug development arm of the Cystic Fibrosis Foundation, has endorsed its Phase 2 clinical trial assessing CFTR amplifi...
Source: SeekingAlpha
Date: April, 17 2018 08:43
Proteostasis Receives Endorsement from the Cystic Fibrosis Foundation's Therapeutic Development Network for the Study of the Company's Amplifier, PTI-428, in CF Subjects on Background Symdeko(TM) Therapy
CAMBRIDGE, Mass. , April 17, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional prote...
Source: PR Newswire
Date: April, 17 2018 07:10
After Hours Gainers / Losers (04/06/2018)
Top gainers: CIFS +2.6% . BPT +2.4% . VEON   +1.4% . AMRN   +1.4% . More news on: China Internet Nationwide Financial Services Inc., BP Prudhoe Bay Royalty Trust, VEON Ltd. ADS, Stocks on the move, , News on ETFs, Read more ...
Source: SeekingAlpha
Date: April, 06 2018 17:34
Blog Exposure - FDA Granted Fast Track Designation to Proteostasis Therapeutics' Triple Combination Program for Cystic Fibrosis
Stock Monitor: Red Hat Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 6, 2018 / Active-Investors.com has just released a free research report on Proteostasis Therapeutics, Inc. (NASDAQ: PTI ). If you want access to this report all you need to do is sign up now by clicking t...
Source: ACCESSWIRE IA
Date: April, 06 2018 07:00
Your Daily Pharma Scoop: Tenax Surges, Eli Lilly's CYRAMZA, Cellectics Public Offering
A nalysis focus: Tenax Therapeutics Tenax Therapeutics (TENX) rose nearly 100% in early trading on Wednesday as the company announced results of its pre-investigational New Drug (pre-IND) meeting with the FDA with regard to the phase 2 study in the use of levosimendan for treatm...
Source: SeekingAlpha
Date: April, 05 2018 08:00
Midday Gainers / Losers (4/4/2018)
Gainers: TENX +75% . RXII +25% . INTX +19% . VCEL +18% . PTI +16% . RTTR +15% . TOPS +17% . CPRX +15% . FTD +13% . OSN +13% . More news on: Tenax Therapeutics, Inc., RXI Pharmaceuticals Corporation, Intersections, Inc., Stocks on the move, , Read more ....
Source: SeekingAlpha
Date: April, 04 2018 12:41
Premarket Gainers as of 9:05 am (04/04/2018)
ASTC +23%  as its new explosives trace detector, the TRACER 1000, has entered into Developmental Test and Evaluation at the U.S. Department of Homeland Security Transportation Security Laboratory. More news on: Astrotech Corporation, Tenax Therapeutics, Inc., CASI Pharmaceu...
Source: SeekingAlpha
Date: April, 04 2018 09:17
Proteostasis Therapeutics receives Fast Track Designation for triple combination program in patients with cystic fibrosis
The FDA grants Fast Track Designation for Proteostasis Therapeutics' (NYSE: PTI ) triple combination program for the treatment of cystic fibrosis. More news on: Proteostasis Therapeutics, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: April, 04 2018 06:23

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-214.984.985.114.88233,496
2018-05-185.004.965.044.96170,420
2018-05-175.105.035.154.89450,860
2018-05-165.455.115.455.08351,253
2018-05-155.265.475.665.2108561,971

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-2263,389111,31556.9456Short
2018-05-2147,44691,50851.8490Short
2018-05-1840,13363,24963.4524Short
2018-05-17148,934202,08473.6991Short
2018-05-1630,207127,07323.7714Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PTI.


About Proteostasis Therapeutics, Inc. (NASDAQ: PTI)

Logo for Proteostasis Therapeutics, Inc. (NASDAQ: PTI)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $180,343,862 - 05/11/2018
  • Issue and Outstanding: 34,482,574 - 03/12/2018

 


Recent Filings from (NASDAQ: PTI)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: May, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 07 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 23 2018
Pre-effective amendment to an S-3 filing
Filing Type: S-3/AFiling Source: edgar
Filing Date: April, 19 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 19 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 17 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: April, 10 2018

 

 


Daily Technical Chart for (NASDAQ: PTI)

Daily Technical Chart for (NASDAQ: PTI)


Stay tuned for daily updates and more on (NASDAQ: PTI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: PTI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PTI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of PTI and does not buy, sell, or trade any shares of PTI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/